All In Biotech

Drug Trial Radar · NCT03206138

Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.

A Randomized, Open-label Study to Evaluate the Safety and Efficacy of GX-188E, a DNA Therapeutic Vaccine Administered Intramuscularly by Electroporation, With GX-I7 Intravaginal Application or Imiquimod Topical Application in HPV16 and/or 18 Positive Patients With CIN3.

Last checked: Nov 19, 2026Latest source record: Jul 2, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

50

Planned (sponsor's estimate)

Start

May 30, 2017

Primary completion

Oct 2018

Study completion Oct 2018

Sponsor

Lead sponsor
Seoul St. Mary's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Genexine, Inc.
First posted
Jul 2, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 19 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to investigate the safety and efficacy of GX-188E administered IM plus local administration of GX-I7 or Imiquimod at cervix in subjects with cervical intraepithelial neoplasia (CIN) 3.

Conditions

  • Cervical Intraepithelial Neoplasia 3

Interventions

  • GX-188E, GX-I7Biological

    Experimental: 1mg of GX-188E administered IM using EP device 3 times and 3mg of GX-I7 administered in cervix 4 times.

  • GX-188E, ImiquimodBiological

    1mg of GX-188E administered IM using EP device 3 times and 12.5mg of Imiquimod application at cervix 8 times.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ratio of subjects who have histopathological regression of cervical lesions to CIN 1 or less in HPV 16 or 18-associated CIN3 subjects.Time frame: at week 20

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul St. Mary's hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.